سعر ميتفيلدازون 50/1000مجم 30 قرص 2024

Vildagliptin 50 mg + metformin hydrochloride 1000 mg film-coated tablets, 30 tablets (3 strips) (Metvildazone, Averroes Pharma).

• Adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on metformin alone, in patients already taking vildagliptin and metformin as separate tablets, or in combination with other antidiabetic medicines including insulin when these are insufficient.Population: Adults with type 2 diabetes mellitusEuropean Medicines Agency (EMA)

• Common: nausea, vomiting, diarrhoea, abdominal pain, flatulence, constipation, reflux, dizziness, headache, tremor, upper respiratory infection, nasopharyngitis, rash, pruritus, hyperhidrosis. Uncommon: hypoglycaemia, loss of appetite, metallic taste, pancreatitis, hepatitis, urticaria. Very rare: lactic acidosis, reduced vitamin B12 absorption. Not known: bullous skin lesions including bullous pemphigoid, cutaneous vasculitis.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity; any acute metabolic acidosis (lactic acidosis, diabetic ketoacidosis); diabetic pre-coma; severe renal failure (GFR <30 ml/min); acute conditions that may alter renal function (dehydration, severe infection, shock, intravascular iodinated contrast); diseases causing tissue hypoxia (cardiac or respiratory failure, recent myocardial infarction, shock); hepatic impairment; acute alcohol intoxication or alcoholism; breastfeeding.International label, same formulation · European Medicines Agency (EMA)

• Lactic acidosis (very rare, serious) mainly with acute worsening of renal function, cardiorespiratory illness or sepsis; stop temporarily in dehydration and start drugs that impair renal function (antihypertensives, diuretics, NSAIDs) with caution.International label, same formulation · European Medicines Agency (EMA)
• Rare hepatic dysfunction (including hepatitis) with vildagliptin; check liver function before treatment and every three months in the first year, then periodically; stop if ALT/AST persistently 3 times ULN or more, or jaundice occurs.International label, same formulation · European Medicines Agency (EMA)
• Vildagliptin has been associated with acute pancreatitis; stop if suspected and do not restart if confirmed.International label, same formulation · European Medicines Agency (EMA)

• Iodinated contrast agentsStop metformin before or at the time of the procedure and restart no earlier than 48 hours after, if renal function is stable.European Medicines Agency (EMA)
• NSAIDs, ACE inhibitors, angiotensin II receptor antagonists and diureticsMay impair renal function and raise lactic acidosis risk; monitor renal function closely.European Medicines Agency (EMA)
• Glucocorticoids, beta2-agonists and diureticsIntrinsic hyperglycaemic activity; more frequent blood glucose monitoring may be needed.European Medicines Agency (EMA)

• No adequate human data; animal studies with vildagliptin showed reproductive toxicity at high doses; Eucreas should not be used during pregnancy.International label, same formulation · European Medicines Agency (EMA)
• Contraindicated during breastfeeding (metformin passes into milk in low amounts with potential neonatal hypoglycaemia; no human data for vildagliptin).International label, same formulation · European Medicines Agency (EMA)

• Vildagliptin: Selective DPP-4 inhibitor increasing endogenous GLP-1 and GIP.
• Metformin hydrochloride: Decreases hepatic glucose production, decreases intestinal glucose absorption and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; insulin secretion remains unchanged (US label).